Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research

Rhea-AI Summary

Science 37 (NASDAQ:SNCE) and Catalent have announced a strategic partnership to revolutionize clinical trial accessibility through direct-to-patient delivery of investigational medicinal products (IMPs). The collaboration has demonstrated significant success across 17 studies, enrolling 1,700 patients with an average of 26% of total study populations through a single Direct-to-Patient Site.

The partnership has already facilitated over 6,400 shipments to study participants, achieving an enrollment rate of 9 patients per month - equivalent to more than 15 traditional brick-and-mortar locations. This integrated solution offers sponsors a streamlined approach with a single contract and budget, while expanding access to underserved populations.

Positive

• Successfully enrolled 1,700 patients across 17 studies through direct-to-patient model
• Achieved 26% average enrollment of total study population through a single Direct-to-Patient Site
• Enrollment rate equivalent to more than 15 brick-and-mortar locations
• Completed over 6,400 successful shipments to study participants
• Streamlined operations through single contract and budget model

Negative

• None.

Insights

Healthcare Technology Analyst

Science 37's partnership with Catalent enhances clinical trial accessibility, accelerating enrollment and boosting geographic reach with impressive early results.

This partnership between Science 37 and Catalent represents a significant operational advancement in decentralized clinical trials. The collaboration directly addresses one of the most challenging aspects of at-home clinical research—the secure and timely delivery of investigational medicinal products to participants' homes across diverse locations.

The preliminary data from this partnership shows compelling operational metrics: across 17 studies, they've enrolled nearly 1,700 patients, with each Direct-to-Patient Site enrolling an average of 26% of the total study population. The enrollment rate of 9 patients per month is particularly notable, as it's equivalent to the output of over 15 traditional research locations. With 6,400+ shipments already delivered, the scale of implementation is substantial.

This model creates value through several mechanisms: it expands the geographic reach of clinical trials, potentially increases diversity in study populations, accelerates enrollment timelines, and streamlines operations under a unified contract structure. For pharmaceutical sponsors, this translates to potential cost efficiencies and faster time-to-market for new treatments.

The real innovation here is the operational integration—creating what amounts to a virtual clinical trial site with the logistical capabilities to handle sensitive medical products. By removing geographic barriers to participation, this approach may help address the persistent industry challenge of slow enrollment and limited diversity in clinical research populations.

MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, and Catalent^®, a global leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply, announced a strategic partnership redefining how investigational medicinal products (IMPs) are delivered directly to patients’ homes for clinical research.

Through this collaboration, Catalent supports Science 37’s Direct-to-Patient Clinical Trial Site model by providing reliable, efficient shipping and logistics services for study medications, ensuring rapid and secure delivery of IMPs across geographies and enabling patients to participate in clinical research from the comfort of their homes, regardless of their location.

“Catalent’s expertise in direct-to-patient logistics is a key enabler of our mission to expand access to clinical trials,” said Tyler Van Horn, CEO at Science 37. “By removing geographic barriers, we’re not only reaching more diverse patient populations, we’re also driving faster enrollment and generating high-quality data that helps bring treatments to market sooner.”

Science 37 and Catalent have partnered to refine the IMP supply chain for at-home trial participation and visit execution. Across 17 studies, Catalent and Science 37's partnership enrolled nearly 1,700 patients by bringing clinical trials directly into the home, enrolling an average 26% of the total study population in a single Direct-to-Patient Site, with 9 patients enrolled per month or the equivalent of more than 15 brick-and-mortar locations in each instance. To date, the partnership has delivered over 6,400 shipments to study participants.

This integrated solution offers sponsors an end-to-end clinical trial site under a single contract and budget, streamlining operations, improving enrollment speed and retention rates, and expanding access to underserved and geographically dispersed populations.

“Our partnership with Science 37 transforms the clinical trial experience, bringing research directly to participants while preserving the rigor and efficiency on which sponsors rely,” said Ricky Hopson, President, Clinical and Specialty Services, and Chief of Staff at Catalent. “Together, we’re advancing a more inclusive and patient-centered future for clinical research, without compromising precision or quality.”

To learn more about how Science 37 and Catalent are transforming clinical research, visit www.science37.com and www.catalent.com.

About Catalent

Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually.

For more information, visit www.catalent.com.

About Science 37

Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes for all. Our solutions empower life sciences companies to reach diverse populations beyond traditional means of conducting clinical research. To learn more, visit www.science37.com or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries

Science 37
pr@science37.com

FAQ

What is the partnership between Science 37 (SNCE) and Catalent?

The partnership enables direct-to-patient delivery of investigational medicinal products (IMPs) for clinical trials, allowing patients to participate in research from home regardless of location.

How many patients has the Science 37-Catalent partnership enrolled?

The partnership has enrolled 1,700 patients across 17 studies, with an average of 26% of total study populations through a single Direct-to-Patient Site.

What is the enrollment rate achieved by Science 37's Direct-to-Patient model?

The model achieves 9 patients enrolled per month, equivalent to the capacity of more than 15 traditional brick-and-mortar locations.

How many shipments has the Science 37-Catalent partnership delivered?

The partnership has successfully delivered over 6,400 shipments to study participants.

What are the benefits of Science 37's Direct-to-Patient Clinical Trial Site model?

The model offers streamlined operations, improved enrollment speed, better retention rates, and expanded access to underserved and geographically dispersed populations, all under a single contract and budget.